Novel Treatment for Severe Malaria

A single new drug, KAE609, is being developed to treat severe malaria—the form of the disease that kills hundreds of thousands of children each year. Severe malaria occurs when *Plasmodium* parasites overwhelm the body, causing organ failure, coma, and death. Current treatments rely on intravenous artesunate, but drug resistance is emerging in Southeast Asia, threatening global progress. KAE609 is a novel compound that attacks the parasite in a different way, potentially bypassing existing resistance mechanisms. This matters because without new drugs, severe malaria could become untreatable in some regions, reversing decades of gains in child survival. If KAE609 reaches market, Novartis plans to use a tiered-pricing strategy to make it affordable across different income groups. The company will work with the World Health Organization, Medicines for Malaria Venture, and procurement agencies like the Global Fund to distribute the drug through public health systems and donor-funded channels. Success would mean a new, resistance-proof option for the sickest patients—a tool that quietly underpins malaria control programmes and prevents health systems from being overwhelmed by severe cases. This is applied, product-focused research with a clear path to patient impact.